Whitney Ijem
Stock Analyst at Canaccord Genuity
(4.79)
# 575
Out of 4,670 analysts
408
Total ratings
50.3%
Success rate
21.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Whitney Ijem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Maintained: Buy | $20 | $13.45 | +48.70% | 30 | Aug 20, 2026 | |
| RARE Ultragenyx Pharmaceutical | Reiterated: Buy | $81 → $83 | $25.83 | +221.33% | 25 | Aug 20, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $114 | $66.70 | +70.91% | 22 | Aug 19, 2026 | |
| NGNE Neurogene | Maintained: Buy | $180 → $166 | $38.63 | +329.72% | 6 | Aug 12, 2026 | |
| RCKT Rocket Pharmaceuticals | Maintained: Buy | $10 | $3.51 | +184.90% | 23 | Aug 12, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $104 → $106 | $81.50 | +30.06% | 2 | Aug 12, 2026 | |
| GUTS Fractyl Health | Maintained: Buy | $8 | $0.78 | +925.64% | 18 | Aug 12, 2026 | |
| TSHA Taysha Gene Therapies | Maintained: Buy | $17 | $6.09 | +179.15% | 26 | Aug 11, 2026 | |
| OCGN Ocugen | Maintained: Buy | $11 | $1.39 | +691.37% | 6 | Aug 6, 2026 | |
| NTLA Intellia Therapeutics | Maintained: Buy | $49 | $12.84 | +281.62% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $5 | $0.6973 | +617.05% | 25 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $227 → $232 | $142.04 | +63.33% | 22 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $151 → $154 | $110.00 | +40.00% | 31 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 → $78 | $29.76 | +162.10% | 6 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $436 → $442 | $548.05 | -19.35% | 39 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $429 | $236.22 | +81.61% | 36 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 → $38 | $11.85 | +220.68% | 4 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $43 | $5.29 | +712.85% | 15 | May 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $23 | $4.44 | +418.02% | 15 | Apr 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $83 → $114 | $346.58 | n/a | 5 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $18.79 | n/a | 2 | Sep 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $146.12 | n/a | 4 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $127.81 | n/a | 1 | Jan 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $48.37 | n/a | 4 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 → $27 | $96.31 | n/a | 2 | Dec 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $18 | $0.1423 | n/a | 5 | Nov 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $3.11 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $59.50 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $35 | $37.63 | n/a | 1 | Oct 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $16 | $1.96 | n/a | 5 | May 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $1.76 | n/a | 2 | Jan 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.15 | n/a | 1 | May 13, 2014 |
Arcturus Therapeutics Holdings
Aug 20, 2026
Maintained: Buy
Price Target: $20
Current: $13.45
Upside: +48.70%
Ultragenyx Pharmaceutical
Aug 20, 2026
Reiterated: Buy
Price Target: $81 → $83
Current: $25.83
Upside: +221.33%
BioMarin Pharmaceutical
Aug 19, 2026
Reiterated: Buy
Price Target: $114
Current: $66.70
Upside: +70.91%
Neurogene
Aug 12, 2026
Maintained: Buy
Price Target: $180 → $166
Current: $38.63
Upside: +329.72%
Rocket Pharmaceuticals
Aug 12, 2026
Maintained: Buy
Price Target: $10
Current: $3.51
Upside: +184.90%
BridgeBio Pharma
Aug 12, 2026
Maintained: Buy
Price Target: $104 → $106
Current: $81.50
Upside: +30.06%
Fractyl Health
Aug 12, 2026
Maintained: Buy
Price Target: $8
Current: $0.78
Upside: +925.64%
Taysha Gene Therapies
Aug 11, 2026
Maintained: Buy
Price Target: $17
Current: $6.09
Upside: +179.15%
Ocugen
Aug 6, 2026
Maintained: Buy
Price Target: $11
Current: $1.39
Upside: +691.37%
Intellia Therapeutics
Aug 6, 2026
Maintained: Buy
Price Target: $49
Current: $12.84
Upside: +281.62%
Aug 6, 2026
Maintained: Buy
Price Target: $5
Current: $0.6973
Upside: +617.05%
Aug 5, 2026
Maintained: Buy
Price Target: $227 → $232
Current: $142.04
Upside: +63.33%
Aug 5, 2026
Maintained: Buy
Price Target: $151 → $154
Current: $110.00
Upside: +40.00%
Aug 5, 2026
Maintained: Buy
Price Target: $75 → $78
Current: $29.76
Upside: +162.10%
Aug 4, 2026
Maintained: Hold
Price Target: $436 → $442
Current: $548.05
Upside: -19.35%
Aug 3, 2026
Reiterated: Buy
Price Target: $429
Current: $236.22
Upside: +81.61%
Aug 3, 2026
Reiterated: Buy
Price Target: $37 → $38
Current: $11.85
Upside: +220.68%
May 19, 2026
Maintained: Buy
Price Target: $43
Current: $5.29
Upside: +712.85%
Apr 21, 2026
Maintained: Buy
Price Target: $23
Current: $4.44
Upside: +418.02%
Feb 28, 2022
Maintained: Buy
Price Target: $83 → $114
Current: $346.58
Upside: n/a
Sep 15, 2021
Upgraded: Buy
Price Target: n/a
Current: $18.79
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $146.12
Upside: n/a
Jan 4, 2021
Upgraded: Buy
Price Target: n/a
Current: $127.81
Upside: n/a
Jun 25, 2020
Maintained: Hold
Price Target: n/a
Current: $48.37
Upside: n/a
Dec 16, 2019
Maintained: Buy
Price Target: $18 → $27
Current: $96.31
Upside: n/a
Nov 9, 2018
Downgraded: Hold
Price Target: $18
Current: $0.1423
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $3.11
Upside: n/a
Oct 9, 2018
Initiated Coverage: Hold
Price Target: n/a
Current: $59.50
Upside: n/a
Oct 9, 2018
Initiated Coverage: Buy
Price Target: $35
Current: $37.63
Upside: n/a
May 4, 2017
Reiterated: Buy
Price Target: $19 → $16
Current: $1.96
Upside: n/a
Jan 11, 2017
Maintained: Hold
Price Target: n/a
Current: $1.76
Upside: n/a
May 13, 2014
Maintained: Hold
Price Target: n/a
Current: $4.15
Upside: n/a